I couldn't agree more!
I'm unsure why PNV is such a target amongst shorts (previously ranking inside the top few most shorted stocks), but I see the Novosorb product offering enormous potential within the next few years. Not to mention the remaining pipeline of products
The missed target of 2x revenue growth should be seen as merely a blip on the radar, especially given the management team has executed their business decisions so well previously. Unfortunately we're being punished for that IMO. Having said that, holding a commercialised product that sells itself (see any testimonial by any surgeon), and also looking at the number of countries that PNV have expanded into over the past 6 months is another thing altogether. Once these markets mature in a few years time, the SP will be light years ahead of where it currently is.
I echo your thoughts that a few extra dollars into the share price is not out of the question in the short term. Very exciting times ahead!
I couldn't agree more!I'm unsure why PNV is such a target...
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.07 |
Change
0.030(1.47%) |
Mkt cap ! $1.429B | |||
| Open | High | Low | Value | Volume |
| $2.11 | $2.12 | $2.05 | $2.783M | 1.335M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 19976 | $2.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.07 | 9633 | 3 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |